Summary

Genes Chromosomes Cancer. 2012 May;51(5):462-72. doi: 10.1002/gcc.21933. Epub 2012 Feb 3.

Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma.

Abstract:

Homozygous germline mutations of the PARK2 gene are responsible for the development of early-onset Parkinson's disease (PD). Homozygous PARK2 mutations have been also detected in lung adenocarcinoma (LADC). However, since heterozygous PARK2 germline mutations are present in a subset of non-PD individuals, the timing for the occurrence of two-hit PARK2 mutations in LADC progression is unclear. Therefore, we comprehensively analyzed mutations, expression and copy number variations of the PARK2 gene in 267 primary LADCs together with the corresponding noncancerous lung cells and 39 LADC cell lines. Heterozygous germline exonic deletions were detected in five patients with LADC, and loss of heterozygosity including the PARK2 locus was detected in 31/267 (11.6%) LADCs. However, homozygous PARK2 inactivation was not detected in any of them, including the five patients with germline mutations. Homozygous PARK2 inactivation was detected in 6/39 (15%) cell lines, two exonic deletions, one exonic duplication, and three point mutations, while heterozygous PARK2 inactivation was detected in two cell lines (both by exonic deletions). These results strongly indicate that somatic PARK2 mutations occur rarely (or do not occur) in LADC development and that germline PARK2 mutations could contribute to LADC progression but not to LADC development.

日本語要旨:

267例の肺腺がん症例および非がん組織を対象とした全ゲノムコピー数解析の結果、近年がん抑制遺伝子として報告されているPARK2遺伝子が肺腺がんで失活する分子機序として肺細胞変異が大きく寄与していることを見い出した。

PMID:  22302706

前ページへ戻る

PAGE TOP